Parkinson's Disease Trial, Not Yet Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- People who have been diagnosed with Parkinson's disease and have shown a specific type of word or language difficulty based on specialised memory and language tests (confirm with trial site for exact test score thresholds).
- People aged between 50 and 90 years old.
- People who are able to understand and agree to take part in the study, demonstrated by being able to answer questions about what participation involves.
- People who can speak and read English fluently.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People who score below 23 on a standard memory and thinking test (called the MoCA), unless a spouse, adult child, parent, or adult sibling is present and both the person and their support partner are able to provide written agreement to participate.
- People with a history of seizures.
- People who have had unexplained episodes of losing consciousness, as these may be related to changes in the brain or epilepsy.
- People who experience severe or frequent headaches.
- People with an unstable or uncontrolled mental health or psychiatric condition.
- People with a severe traumatic brain injury (assessed using a specific identification method — confirm with trial site).
- People who have or have had a brain tumour.
- People who have had a stroke.
- People who are currently misusing or abusing drugs.
- People with serious or life-threatening illnesses, including heart failure, chronic obstructive pulmonary disease (a lung condition), or active cancer.
- People with Huntington's disease.
- People who have metal implants in the skull or defects in the skull that would affect how the brain stimulation device is used.
- People who have implanted medical devices in the brain, including deep brain stimulators (DBS).
- People who have an implanted pacemaker.
- People who have any implant that is activated by electricity, magnetism, or mechanical means.
- People with cardiac, neural, or medication implants.
- People who have vascular clips or other electrically sensitive devices in the brain.
- People with damaged skin at the areas of the body where the stimulation device would be placed.
- People with skin conditions such as dermatitis, psoriasis, or eczema.
- People who are pregnant.
- People whose only speech or language difficulty is dysarthria (a motor-based speech problem affecting how words are physically produced, rather than word-finding or language ability).
- People taking certain medications that may interact with the brain stimulation or brain activity recording used in this trial, including: anti-convulsants, carbamazepine, sulpiride, pergolide, lorazepam, rivastigmine, dextromethorphan, D-cycloserine, flunarizine, ropinirole, citalopram, or stimulant medications.
- People who do not speak English, as the screening forms, questionnaires, and tests used in this trial are only available in English.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: John Hart, MD, Callier Clinical Research Center, The University of Texas at Dallas
Phone: 972-883-4846
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Treatment group differences in change from Baseline to 1-week Post-Treatment on Category Fluency; Treatment group differences in change from Baseline to 2-months Post-Treatment on Category Fluency; Treatment group differences in change from Baseline to 1-week Post-Treatment on Phonemic Fluency; Treatment group differences in change from Baseline to 2-months Post-Treatment on Phonemic Fluency
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.